Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progression of two psychedelic drug candidates: CYB003 and CYB004. According to Cybin, the studies were completed in record time, in part due to close collaboration with the company’s partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Michael Palfreyman, Cybin’s chief R&D officer, in a recent update. “We look forward to rapid progress towards clinical studies.”
To view the full article, visit https://ibn.fm/ryB1i
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.